Cellebrite DI (CLBT) EBITDA (2020 - 2026)

Cellebrite DI has reported EBITDA for 7 years, with the latest figure at $6.9 million in Q2 2026.

• On a quarterly basis, EBITDA fell 51.8% year-over-year to $6.9 million in Q2 2026; TTM through Jun 2026 was $55.9 million, a 9.69% decrease from a year earlier, with the FY2025 full-year figure at $127.6 million, up 28.43% from the prior year.
• EBITDA was $6.9 million for Q2 2026 at Cellebrite DI, down from $9.1 million in the prior quarter.
• The five-year high for EBITDA was $22.8 million in Q4 2023, with the low at -$5.6 million in Q2 2022.
• Average EBITDA over 5 years is $11.2 million, with a median of $12.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: EBITDA plunged 168.11% in 2022, then jumped 6699.26% in 2024.
• Over 5 years, EBITDA stood at $16.1 million in 2022, then surged by 41.22% to $22.8 million in 2023, then slumped by 30.89% to $15.7 million in 2024, then soared by 32.29% to $20.8 million in 2025, then sank by 66.6% to $6.9 million in 2026.
• The last three EBITDA figures came in at $6.9 million (Q2 2026), $9.1 million (Q1 2026), and $20.8 million (Q4 2025), per Business Quant data.